海普瑞签署分销协议
财中社1月2日电海普瑞（002399/09989）发布关于签订分销协议的公告。公司于2024年12月31日与浙江永太药业有限公司签订分销协议，获得在美国全境商业化加巴喷丁胶囊的许可。根据协议，海普瑞将以约定价格向永太药业购买该药品，并负责其在美国市场的商业化工作，除供货价格外无需支付其他款项。
加巴喷丁是一种常用的抗癫痫药物，在美国的销售额约为4.63亿美元。此次合作体现了公司国际化经营的战略，利用永太药业的产品质量和成本控制优势，结合公司在美国市场的销售经验，旨在促进标的药品的海外市场营销。这一合作不仅是对公司海外市场营销能力的认可，也为未来与其他医药企业的合作积累了经验。
2024年前三季度，海普瑞实现收入40.69亿元，归母净利润7.80亿元。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10